Skip to main content
Premium Trial:

Request an Annual Quote

Lynx, Wilex Will Study Gene Expression Changes With New Cancer Drug

NEW YORK, April 23-Lynx Therapeutics and Wilex AG will work together to identify genes regulated by Wilex' lead compound for renal cell carcinoma, the companies said today.

 

Lynx will use its Massively Parallel Signature Sequencing system to analyze gene expression differences in samples treated with the Wilex compound.

 

Wilex CEO Olaf Wilhelm said in a statement that the Lynx technology may reveal markers that can predict patient response to drug therapy, making it possible to identify those patient subpopulations most likely to benefit from the new drug. The process may also reveal additional therapeutic targets for combination drug treatment.

 

Lynx will receive service payments from Wilex.

 

The Wilex compound, WX-G250, is designed to induce antibody dependent cellular cytoxicity in renal cell carcinomas. It is currently in phase II clinical trials.

 

Renal cell carcinoma is the tenth most common cancer in the Unites States, and causes more than 12,000 deaths annually.

 

Wilex, a biopharmaceutical company based in Munich, focuses on treatments for cancer.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.